Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
C LeightonG Cairncross

Abstract

To review the outcomes of patients with low-grade glioma diagnosed by modern imaging and treated at a center where postponing radiotherapy was common practice. We reviewed the records of patients (age > or = 18 years) with pathologically confirmed supratentorial low-grade fibrillary astrocytoma, oligodendroglioma, and mixed glioma treated at a regional cancer center in Canada between 1979 and 1995. Median survival for the entire group (N = 167; mean age 40.6 years) was 10.5 years with 5- and 10-year survival rates of 72% and 50%, respectively. Median progression-free survival was 4.9 years with 5- and 10-year progression-free rates of 50% and 12%, respectively. Overall and progression-free survivals were longer for patients with an oligodendroglioma or mixed glioma than with astrocytoma (median 13 v 7.5 years, P = .003; progression-free 5.6 v 4.4 years, p = .054). Age at diagnosis < or = 40 years, seizures at presentation, minimal residual tumor after surgery, Karnofsky performance status > or = 70, and oligodendroglioma or mixed glioma pathology were associated with significantly longer median survival on univariate and multivariate analyses. Radiotherapy deferred until tumor progression (v immediate radiotherapy) was associat...Continue Reading

Citations

Feb 17, 1998·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·C F Hess
Mar 22, 2003·Laboratory Investigation; a Journal of Technical Methods and Pathology·Kimmo J HatanpaaKarin D Berg
Jun 11, 2003·American Journal of Clinical Oncology·Steven J FeigenbergWilliam A Friedman
May 26, 2004·Current Treatment Options in Neurology·Edward J. Dropcho
Apr 14, 2005·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Warren P Mason
Feb 26, 2005·The British Journal of Radiology·S-A YehE-Y Huang
Nov 9, 2005·Expert Review of Neurotherapeutics·Bakhtiar Yamini, Christian W Sikorski
Sep 6, 2005·Neuroradiology·Matthias Philipp LichyHeinz-Peter Schlemmer
Mar 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frederick F Lang, Mark R Gilbert
Nov 10, 2009·Expert Review of Anticancer Therapy·Zarnie LwinWarren P Mason
Jun 30, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Nader Sanai, Mitchel S Berger
Feb 4, 2010·Neurosurgical Focus·Nader Sanai, Mitchel S Berger
Jul 16, 2010·Expert Review of Molecular Diagnostics·Andreana L Rivera, Christopher E Pelloski
Sep 3, 2010·Acta neurochirurgica·Michael D JenkinsonBrian Haylock
May 24, 2011·International Journal of Molecular Imaging·Anja Smits, Brigitta G Baumert
Nov 1, 2012·Neuro-oncology·Roberta RudàRiccardo Soffietti
Jan 5, 2013·Arquivos de neuro-psiquiatria·André de Macedo BiancoSuely K Nagahashi Marie
Feb 1, 2014·Carcinogenesis·Mian GuoZhiguo Lin
Aug 12, 2014·Journal of Neuro-oncology·Meghan Murphy, Ian F Parney
Feb 13, 2015·Science Translational Medicine·Michael JermynFrederic Leblond
Oct 4, 2014·Current Opinion in Oncology·Marco Riva, Lorenzo Bello
Apr 25, 2015·Journal of Neurosurgery·Shawn L Hervey-JumperMitchel S Berger
Jan 19, 2016·Journal of Neuro-oncology·Severina LeuLuigi Mariani
Nov 30, 2000·Current Treatment Options in Neurology·P A Forsyth, W H Roa
Jul 3, 2003·British Journal of Cancer·P H WesselsA Twijnstra
Apr 6, 2001·Seminars in Surgical Oncology·K K HerfarthJ Debus
Mar 1, 2005·Journal of Neuro-oncology·S E CombsJ Debus
Nov 6, 2007·Nature Clinical Practice. Neurology·Nader PouratianDavid Schiff
Nov 24, 2006·The Neurologist·Andrew D Norden, Patrick Y Wen
May 19, 2005·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Carmen González San SegundoJuan Antonio Santos Miranda
Jan 4, 2008·The New England Journal of Medicine·Nader SanaiMitchel S Berger
Jun 27, 2008·Current Treatment Options in Neurology·Sandeep MittalGeoffrey R Barger
Mar 17, 2009·Journal of Neurosurgery·Hamdy El-HateerMarie-Christine Guiot
May 23, 2008·Neurosurgery·Nader Sanai, Mitchel S Berger
Mar 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Justin S SmithMitchel S Berger

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.